These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8845545)

  • 1. Another perspective on monitoring anticoagulation therapy.
    Burnakis TG
    Ann Pharmacother; 1995 Oct; 29(10):1045-6. PubMed ID: 8845545
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring the anti-Xa anticoagulants, from heparin to eliquis.
    Fritsma GA
    Clin Lab Sci; 2013; 26(1):48-53. PubMed ID: 23479837
    [No Abstract]   [Full Text] [Related]  

  • 4. Anticoagulation monitoring during extracorporeal membrane oxygenation: is anti-factor Xa assay (heparin level) a better test?*.
    Nguyen T; Musick M; Teruya J
    Pediatr Crit Care Med; 2014 Feb; 15(2):178-9. PubMed ID: 24492189
    [No Abstract]   [Full Text] [Related]  

  • 5. Dermatan sulfate anticoagulation: future replacement for heparin?
    Gravlee GP
    J Cardiothorac Vasc Anesth; 1995 Jun; 9(3):237-9. PubMed ID: 7669955
    [No Abstract]   [Full Text] [Related]  

  • 6. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation assays.
    Bates SM; Weitz JI
    Circulation; 2005 Jul; 112(4):e53-60. PubMed ID: 16043649
    [No Abstract]   [Full Text] [Related]  

  • 8. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of prekallikrein deficiency during cardiac surgery.
    Eeckhoudt SL; Momeni M; Matta A; Latinne D; Arnout J; Hermans C
    Thromb Haemost; 2010 Apr; 103(4):866-7. PubMed ID: 20135073
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome.
    Mehta TP; Smythe MA; Mattson JC
    Pharmacotherapy; 2011 Dec; 31(12):1221-31. PubMed ID: 22122183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency.
    Oram MP; Mumford AD; Morse C; Underwood S
    J Cardiothorac Vasc Anesth; 2006 Aug; 20(4):580-2. PubMed ID: 16884995
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass.
    Gu YJ; Huyzen RJ; van Oeveren W
    Anesth Analg; 1996 Aug; 83(2):433. PubMed ID: 8694335
    [No Abstract]   [Full Text] [Related]  

  • 15. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
    Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current considerations in the use of the APTT in monitoring unfractionated heparin.
    Nelson DE
    Clin Lab Sci; 1999; 12(6):359-64. PubMed ID: 10724634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.
    Simko RJ; Tsung FF; Stanek EJ
    Ann Pharmacother; 1995 Oct; 29(10):1015-21; quiz 1061. PubMed ID: 8845539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin.
    Gouin-Thibault I; Samama MM
    Thromb Haemost; 2009 May; 101(5):986-7. PubMed ID: 19404557
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
    Kikkert WJ; van Nes SH; Lieve KV; Dangas GD; van Straalen J; Vis M; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
    Thromb Haemost; 2013 May; 109(5):961-70. PubMed ID: 23446910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.